Positive Long-Term China Safety Data For Ascletis’s Oral Acne Contender
Following the recent acceptance of a China NDA for first-in-class drug denifanstat for acne in China, Ascletis has announced positive topline results from an open-label Phase III trial focusing on the product’s long-term safety.
Scrip - January 30, 2026

AstraZeneca Bets $18.5bn On CSPC’s Sustained-Release And AI Peptide Platforms In Weight Management
UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.
Scrip - January 30, 2026

Execs On The Move: January 19–23, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 29, 2026

Hey Doc, What’s That Sound? FDA Clearance Broadens Scope Of AI Heart Murmur Detection Platform
The US FDA has granted clearance to eMurmur, broadening the use of its AI-powered software platform. The innovative system identifies primary heart sounds to detect abnormal murmurs as they occur.
Medtech Insight - January 29, 2026

Illumina Pins 2026 Growth On Clinical Sequencing As Research Spending Stays Constrained
Illumina CEO Jacob Thaysen told JPMorgan analysts that clinical consumables, NovaSeq X adoption will anchor company’s near-term outlook amid muted academic demand.
Medtech Insight - January 29, 2026

When Brain-Computer Interfaces Fail, Human Trial Participants Have Few Options
In this final part of a three-part series, Medtech Insight spoke with a neuroethicist and the first person in a trial using a BCI implant for stimulating hand movement. This story explores ethical considerations that arise when projects can no longer support patients with implanted devices.
Medtech Insight - January 29, 2026

Revlon ColorSilk Claims Focus Of Henkel-Prompted NAD Assessment
New York-based Revlon was able to demonstrate substantiation for two claims for its namesake ColorSilk with bond Repair Complex hair color, while committing to modifying or discontinuing several other claims that the National Advertising Division concluded were not supported.
HBW Insight - January 30, 2026

Kenvue Shareholder Meeting Shows Strong Support To Accept Kimberly-Clark’s Nearly $50Bn Offer
Both companies announced that during special meetings on Jan. 29, their shareholders voted nearly unanimous support for Kimberly-Clark’s $48.7bn acquisition proposed in November at $3.50 per share plus 0.14625 share for each Kenvue share.
HBW Insight - January 30, 2026

Alvotech Secures Immediate Launch Of Eylea Biosimilar In The UK And Canada
Alvotech has ticked off all of the remaining patent-related matters for its aflibercept biosimilar, with multiple market entries expected in 2026.
Generics Bulletin - January 29, 2026

Teva Positions For Long-Term Biosimilars Growth With 10 Launches From 2028
Teva says it has 10 additional biosimilars in development for launch from 2028 onwards, extending its portfolio beyond 2027 as it targets European growth and expands through partnerships.
Generics Bulletin - January 29, 2026

Celltrion Reassures US Tariff Resilience After Trump Threatens Korean Trade Deal U-Turn
Even though the ink has long dried on the US-South Korea trade deal, new threats have prompted Celltrion to reiterate its “fundamental solution” to tariff concerns.
Generics Bulletin - January 29, 2026

Anticipating 2026 ACC/AHA Guideline Updates That Will Impact The Cardiometabolic Landscape
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
In Vivo - January 27, 2026